Similar to bispecific antibodies like blinatumomab, that selectively redirect T lymphocytes to cancer cells via binding to CD3 [40], bispecific and trispecific molecules, which recruit innate killer cells to the tumor by engaging CD16, natural cytotoxicity receptors, or NKG2D, are gaining increasing interest and clinical relevance [20,41,42,43]. This evidence concerns the gene KLRK1 and cancer.